| Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia C Roddie, J Dias, MA O'Reilly, M Abbasian, A Cadinanos-Garai, ... Journal of Clinical Oncology 39 (30), 3352, 2021 | 76 | 2021 |
| Non-viral chimeric antigen receptor (CAR) T cells going viral H Balke-Want, V Keerthi, A Cadinanos-Garai, C Fowler, N Gkitsas, ... Immuno-Oncology and Technology 18, 100375, 2023 | 12 | 2023 |
| ALLCAR19: updated data using AUTO1, a novel fast-off rate CD19 CAR in relapsed/refractory B-cell acute lymphoblastic Leukaemia and other B-cell malignancies C Roddie, MA O'Reilly, MAV Marzolini, L Wood, J Dias, AC Garai, ... Blood 136, 3-4, 2020 | 7 | 2020 |
| AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival V Mehra, G Agliardi, JDA Pinto, MS Shafat, AC Garai, L Green, A Hotblack, ... Journal for Immunotherapy of Cancer 11 (9), 2023 | 5 | 2023 |
| Release assays and potency assays for CAR T-cell interventions J Dias, A Cadiñanos-Garai, C Roddie Potency Assays for Advanced Stem Cell Therapy Medicinal Products, 117-137, 2023 | 2 | 2023 |
| Early safety and efficacy findings of auto1 (cat19), a fast-off rate cd19 car, in relapsed/refractory indolent b cell lymphomas C Roddie, J Dias, M O'Reilly, AC Garai, L Bosshard, M Abbasian, ... HemaSphere, 361-362, 2021 | 1 | 2021 |
| Advancing in vivo genome editing: B cell engineering via adenoviral delivery systems A Cadinanos-Garai, M Abou-el-Enein Molecular Therapy 31 (9), 2554-2556, 2023 | | 2023 |
| Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL) C Roddie, J Dias, MA O'Reilly, A Cadinanos Garai, L Green, M Abbasian, ... Blood 138 (Supplement 1), 3823-3823, 2021 | | 2021 |
